Compare Palo Alto Networks Inc (PANW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Twist Bioscience Corp — how do they compare? Palo Alto Networks Inc trades at $406.5 (market cap $331.76B), while Twist Bioscience Corp trades at $165.14 (market cap $10.08B). The key difference: Palo Alto Networks Inc is far larger — about 32.9× Twist Bioscience Corp's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Twist Bioscience Corp for 27 Days on average.
| PANW | TWST | |
|---|---|---|
Market Cap | $331.76B | $10.08B |
Volume | 3,886,927 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $419.91 | $205.00 |
52-Week Low | $141.67 | $25.45 |
Typical Hold Time | 82 Days | 27 Days |
Enterprise Value | $331.19B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but maintains a bullish technical outlook with strong moving average signals. The company demonstrates robust revenue growth, reaching $9.22B in 2025, though net margins compressed to 2.67%. Recent AI security initiatives, including Unit 42 AI defense service, position PANW for continued growth in the cybersecurity sector.
PANW presents a mixed investment case with strong AI-driven growth potential offset by premium valuations (P/E 1,013.93, P/S 26.99). Analyst consensus remains strongly bullish (72% buy ratings) with a $398.70 price target. Key risks include valuation sensitivity and competitive pressures in the rapidly evolving cybersecurity landscape.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
